0000874015-20-000160.txt : 20201130
0000874015-20-000160.hdr.sgml : 20201130
20201130184943
ACCESSION NUMBER: 0000874015-20-000160
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201125
FILED AS OF DATE: 20201130
DATE AS OF CHANGE: 20201130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HOUGEN ELIZABETH L
CENTRAL INDEX KEY: 0001074773
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 201359381
MAIL ADDRESS:
STREET 1: 10070 BARNES CANYON ROAD
STREET 2: C/O MOLECULAR BIOSYSTEMS INC
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330336973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2020-11-25
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001074773
HOUGEN ELIZABETH L
C/O IONIS PHARMACEUTICALS, INC.
2855 GAZELLE CT.
CARLSBAD,
CA
92010
0
1
0
0
EVP, Finance & CFO
Common Stock
2020-11-25
2020-11-25
4
M
0
21680
39.87
A
54175
D
Common Stock
2020-11-25
2020-11-25
4
S
0
21680
50.05
D
32495.0
D
Non-Qualified Stock Option (right to buy)
39.87
2020-11-25
2020-11-25
4
M
0
21680
0.0
D
2015-01-02
2021-01-01
Common Stock
0.0
0
D
Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020.
Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on October 2, 2020.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.
/s/Patrick R. O'Neil, attorney-in-fact
2020-11-30